Allos Therapeutics Inc., of Westminster, Colo., said data from the Phase II PROPEL study published in the Journal of Clinical Oncology showed that Folotyn (pralatrexate) in relapsed or refractory peripheral T-cell lymphoma patients produced an overall response rate of 29 percent, with 11 percent of patients experiencing a complete response or unconfirmed complete response. Folotyn was granted accelerated approval in PTCL in 2009.